@FiercePharma: IDEXX misses earnings target, dampens 2015 forecast. FierceAnimalHealth story | Follow @FiercePharma
@EricPFierce: GSK licks Nicorette manufacturing problems; 'Minis' are back. FiercePharmaManufacturing report | Follow @EricPFierce
@CarlyHFierce: After topping Q1 estimates, Valeant hikes guidance on Salix buy. ICYMI yesterday | Follow @CarlyHFierce
> Celgene's ($CELG) profit more than doubled as its top-selling blood cancer drug Revlimid continued its growth march in the U.S., but overall sales fell short of analyst estimates. Story | Report
> Bristol-Myers Squibb ($BMY) said the FDA accepted its application for broader use of its cancer drug Opdivo, in patients newly diagnosed with melanoma. Release
> Shire ($SHPG) has appointed interim CFO Jeff Poulton as its CFO, and he'll also join the company's board of directors. Release
> Belgian drugmaker UCB posted double-digit sales growth in the first quarter, thanks to strong Cimzia performance and a boost in orders for its off-patent epilepsy med Keppra. Report
> Kythera won FDA approval for its injection designed to combat double chin, Kybella, and plans to launch the drug during the second half of this year. Report
> Bristol-Myers Squibb priced a European debt offering worth 1.15 billion euros, with two tranches due in 2025 and 2035. Report
Medical Device News
@FierceMedDev: ICYMI: Kleiner Perkins backs Rapid Micro Biosystems in $25M for microbial detection in quality control. Report | Follow @FierceMedDev
@VarunSaxena2: Drug testing company Cordant raises $12.8M as it seeks to be fragmented industry's one-stop shop. FierceDiagnostics story | Follow @VarunSaxena2
@EmilyWFierce: Researchers Yale used gene editing tech to fix a mutation commonly linked to cystic fibrosis. FierceBiotechResearch article | Follow @EmilyWFierce
> Boston Sci courts hospitals with a pair of deals to boost patient outcomes and lower costs. Story
> Harvard point-of-care handheld cancer diagnostic spinoff WaveGuide raises $13.9M. Report
Biotech News
@FierceBiotech: ICYMI yesterday: Kythera bags FDA approval for its double-chin-shrinking shot. Report | Follow @FierceBiotech
@JohnCFierce: To restate: T-Vec panel demonstrates just how accepting the FDA and its panels are when it comes to "meh" cancer drugs. (Once owned a VTec) | Follow @JohnCFierce
@DamianFierce: Wasn't it odd that $SNTA said Whitaker's new job "allows her to be located closer to her family" in its PR? | Follow @DamianFierce
> With Teva out, OncoGenex shrinks its PhIII lung cancer study. Article
> Sanofi-backed MyoKardia nabs a $46M round for cardio pipeline construction. Report
CRO News
> WuXi's CEO moves to take the CRO private. News
> Icon dampens its outlook despite a strong quarter. Report
> Quintiles scales back its 2015 projections after a mixed quarter. More
> Charles River ticks up its revenue amid a shift in focus. Story
> INC swings to profit and dials up its revenue expectations. Article
Vaccines News
> As California measles cases mounted, so did Merck measles vaccine sales. Item
> 80% leap for Pfizer's U.S. Prevnar sales trounces Q1 estimates. Report
> GSK's shingles candidate more effective than Merck's Zostavax in older adults, study says. Story
> Amgen wins FDA panel nod for T-Vec in melanoma. News
> Final trial results show GSK malaria vaccine's efficacy wanes over time. Article
Pharma Manufacturing News
> FDA wants manufacturers to test APIs in hospital antiseptics. More
> AmerisourceBergen keeps up momentum gained from Walgreens deal. News
> Drug shortages become issue in Teva and Mylan hook-up. Article
> Attix Pharmaceuticals recalls hundreds of APIs from the U.S. News
> Hospira's Rocky Mount warning letter lifted; Pfizer benefits. Story
Pharma Asia News
> India works with Hilleman to help industry avoid waste in vaccines stockpile. Report
> China on standardized quality push for traditional medicines. Story
> Singapore's Temasek piles into Indian pharma to the tune of $567.7M. More
> China devices market set to soar by 2020 as GDP overtakes U.S., report says. Item
> Hospital drug sales noted by Premier Li in China reform push. Article
And Finally... Why do some people get fitter than others? Report